D&O Ongoing Disclosure – Multiple

7 June 2022


Ongoing disclosure notices

Please see attached Ongoing Disclosure Notices for the following directors of Ryman
Healthcare Limited (RYM):

Greg Campbell
Dr David Kerr
Geoff Cumming
Paula Jeffs
Warren Bell
Jo Appleyard
George Savvides
Anthony Leighs
Claire Higgins


The notices relate to shares acquired under the Ryman directors’ fixed share trading plan.

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Ryman Healthcare Limited
Date this disclosure made:
7 June 2022
Date of last disclosure:
10 December 2021
Director or senior manager giving disclosure
Full name(s):
Gregory Shane Campbell
Name of listed issuer:
Ryman Healthcare Limited
Name of related body corporate (if applicable):
Position held in listed issuer:Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Registered holder and beneficial owner
For that relevant interest-
Number held in class before acquisition or disposal:
79,335
Number held in class after acquisition or disposal:
84,312
Current registered holder(s):N/A
Registered holder(s) once transfers are registered:
Gregory Shane Campbell and Nicola Anne
Campbell
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
Multiple
Details of transactions requiring disclosure-
Date of transaction:
31 May 2022 to 3 June 2022
Nature of transaction:
On market purchases in accordance with the
Ryman directors' fixed share trading plan (for
the period from 1 October 2021 to 31 March
2022)
Name of any other party or parties to the transaction (if known):
N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$48,013.12 (being an average of $9.6470 per
share)
Number of financial products to which the transaction related:
4,977

If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal
Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:7 June 2022
Name and title of authorised person:David Bennett, Group Chief Financial Officer
Notes
Use this form to disclose all the acquisitions and disposals by a director or senior
manager of a listed issuer, or of a related body corporate, or in specified derivatives. The
disclosure must be made within—
(
a)
20 w
orking days after the first acquisition or disposal disclosed in this
notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the
Financial Markets Conduct Act 2013; or
(b)in any other case, 5 trading days after the first acquisition or disposal
dis
closed in this notice.

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Ryman Healthcare Limited
Date this disclosure made:
7 June 2022
Date of last disclosure:
6 December 2021
Director or senior manager giving disclosure
Full name(s):
David William Kerr
Name of listed issuer:
Ryman Healthcare Limited
Name of related body corporate (if applicable):
Position held in listed issuer:Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Registered holder and beneficial owner
(together with Deborah Jane Floyd Kerr)
For that relevant interest-
Number held in class before acquisition or disposal:
388,193
Number held in class after acquisition or disposal:
392,609
Current registered holder(s):
N/A
Registered holder(s) once transfers are registered:
David William Kerr and Deborah Jane Floyd
Kerr
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
Multiple
Details of transactions requiring disclosure-
Date of transaction:
31 May 2022 to 3 June 2022
Nature of transaction:
On market purchases in accordance with the
Ryman directors' fixed share trading plan (for
the period from 1 October 2021 to 31 March
2022)
Name of any other party or parties to the transaction (if known):
N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$42,601.15 (being an average of $9.6470 per
share)

Number of financial products to which the transaction related:
4,416
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal
Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
7 June 2022
Name and title of authorised person:David Bennett, Group Chief Financial Officer
Notes
Use this form to disclose all the acquisitions and disposals by a director or senior
manager of a listed issuer, or of a related body corporate, or in specified derivatives. The
disclosure must be made within—
(
a)
20 w
orking days after the first acquisition or disposal disclosed in this
notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the
Financial Markets Conduct Act 2013; or
(b)in any other case, 5 trading days after the first acquisition or disposal
dis
closed in this notice.

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Ryman Healthcare Limited
Date this disclosure made:
7 June 2022
Date of last disclosure:
6 December 2021
Director or senior manager giving disclosure
Full name(s):
Geoffrey A Cumming
Name of listed issuer:
Ryman Healthcare Limited
Name of related body corporate (if applicable):
Position held in listed issuer:Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Relevant interest in fully paid ordinary shares
of RYM held by Karori Capital Limited (a
wholly owned company of G.A. Cumming).
For that relevant interest-
Number held in class before acquisition or disposal:
49,040,716
Number held in class after acquisition or disposal:
49,044,372
Current registered holder(s):
N/A
Registered holder(s) once transfers are registered:
Karori Capital Limited
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
Multiple
Details of transactions requiring disclosure-
Date of transaction:
31 May 2022 to 3 June 2022
Nature of transaction:
On market purchases in accordance with the
Ryman directors' fixed share trading plan (for
the period from 1 October 2021 to 31 March
2022)
Name of any other party or parties to the transaction (if known):
N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$35,269.43 (being an average of $9.6470 per
share)

Number of financial products to which the transaction related:
3,656
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal
Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
7 June 2022
Name and title of authorised person:David Bennett, Group Chief Financial Officer
Notes
Use this form to disclose all the acquisitions and disposals by a director or senior
manager of a listed issuer, or of a related body corporate, or in specified derivatives. The
disclosure must be made within—
(
a)
20 w
orking days after the first acquisition or disposal disclosed in this
notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the
Financial Markets Conduct Act 2013; or
(b)in any other case, 5 trading days after the first acquisition or disposal
dis
closed in this notice.

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Ryman Healthcare Limited
Date this disclosure made:
7 June 2022
Date of last disclosure:
6 December 2021
Director or senior manager giving disclosure
Full name(s):
Paula Natalie Jeffs
Name of listed issuer:
Ryman Healthcare Limited
Name of related body corporate (if applicable):
Position held in listed issuer:Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Registered holder and beneficial owner
For that relevant interest-
Number held in class before acquisition or disposal:
4,668
Number held in class after acquisition or disposal:
8,080
Current registered holder(s):
N/A
Registered holder(s) once transfers are registered:
Paula Natalie Jeffs
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
Multiple
Details of transactions requiring disclosure-
Date of transaction:
31 May 2022 to 3 June 2022
Nature of transaction:
On market purchases in accordance with the
Ryman directors' fixed share trading plan (for
the period from 1 October 2021 to 31 March
2022)
Name of any other party or parties to the transaction (if known):
N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$32,915.56 (being an average of $9.6470 per
share)
Number of financial products to which the transaction related:
3,412

If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal
Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
7 June 2022
Name and title of authorised person:David Bennett, Group Chief Financial Officer
Notes
Use this form to disclose all the acquisitions and disposals by a director or senior
manager of a listed issuer, or of a related body corporate, or in specified derivatives. The
disclosure must be made within—
(a)20 working days after the first acquisition or disposal disclosed in this
notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the
Financial Markets Conduct Act 2013; or
(
b)
in an
y other case, 5 trading days after the first acquisition or dispos
al
disclosed in this notice.

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Ryman Healthcare Limited
Date this disclosure made:
7 June 2022
Date of last disclosure:
6 December 2021
Director or senior manager giving disclosure
Full name(s):
Warren James Bell
Name of listed issuer:
Ryman Healthcare Limited
Name of related body corporate (if applicable):
Position held in listed issuer:Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Registered holder and beneficial owner
For that relevant interest-
Number held in class before acquisition or disposal:
2,090
Number held in class after acquisition or disposal:
5,073
Current registered holder(s):N/A
Registered holder(s) once transfers are registered:Warren James Bell
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
Multiple
Details of transactions requiring disclosure-
Date of transaction:
31 May 2022 to 3 June 2022
Nature of transaction:
On market purchases in accordance with the
Ryman directors' fixed share trading plan (for
the period from 1 October 2021 to 31 March
2022)
Name of any other party or parties to the transaction (if known):
N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$28,777.00 (being an average of $9.6470 per
share)
Number of financial products to which the transaction related:
2,983

If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal
Class of quoted financial products:
Ordinary shares
Nature of relevant interest:
Warren is a director of Hickman Family
Trustees Limited (HFTL) (which is the
registered holder of the shares as trustee of
the Hickman Family Trust) and has control
over the exercise of a right to vote attached to
the shares as an independent director of
HFTL (alongside the other directors of HFTL).
For that relevant interest,-
Number held in class:33,000,000
Current registered holder(s):Hickman Family Trustees Limited
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
7 June 2022
Name and title of authorised person:David Bennett, Group Chief Financial Officer
Notes
Use this form to disclose all the acquisitions and disposals by a director or senior
manager of a listed issuer, or of a related body corporate, or in specified derivatives. The
disclosure must be made within—
(
a)
20 w
orking days after the first acquisition or disposal disclosed in this
notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the
Financial Markets Conduct Act 2013; or

(b) in any other case, 5 trading days after the first acquisition or disposal
disclosed in this notice.

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer: Ryman Healthcare Limited
Date this disclosure made:7 June 2022
Date of last disclosure: 6 December 2021
Director or senior manager giving disclosure
Full name(s):Anthony Cameron Leighs
Name of listed issuer:Ryman Healthcare Limited
Name of related body corporate (if applicable):
Position held in listed issuer:Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products: Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Alisanca Holdings Limited (of which
Anthony Leighs is a shareholder and the
sole director) is the registered holder and
beneficial owner of the shares.
For that relevant interest-
Number held in class before acquisition or disposal:20,590
Number held in class after acquisition or disposal:23,573
Current registered holder(s):N/A
Registered holder(s) once transfers are registered:Alisanca Holdings Limited
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under
the derivative or the value of the derivative is affected by the value of the underlying financial
products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
Mu ltip le
Details of transactions requiring disclosure-
Date of transaction:
31 May 2022 to 3 June 2022
Nature of transaction:
On market purchases in accordance with
the Ryman directors' fixed share trading
plan (for the period from 1 October 2021
to 31 March 2022)
Name of any other party or parties to the transaction (if known):
N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or
disposal. If the consideration was not in cash and cannot be readily by converted into a cash
value, describe the consideration:
$28,777.00 (being an average of $9.6470
per share)
Number of financial products to which the transaction related:
2,983
If the issuer has a financial products trading policy that prohibits directors or senior managers
from trading during any period without written clearance (a closed period) include the following
details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed
during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal
Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable under
the derivative or the value of the derivative is affected by the value of the underlying financial
products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons for
whom it is made.
Signature of director or officer:
Date of signature:7 June 2022
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:
Notes
Use this form to disclose all the acquisitions and disposals by a director or senior manager of
a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must
be made within—
(a) 20 working days after the first acquisition or disposal disclosed in this notice if
the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial
Markets Conduct Act 2013; or

(b) in any other case, 5 trading days after the first acquisition or disposal disclosed
in this notice.

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Ryman Healthcare Limited
Date this disclosure made:
7 June 2022
Date of last disclosure:
6 December 2021
Director or senior manager giving disclosure
Full name(s):
Claire Louise Higgins
Name of listed issuer:
Ryman Healthcare Limited
Name of related body corporate (if applicable):
Position held in listed issuer:Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):
Adam L Higgins Superannuation Fund holds
the shares in which Claire Louise Higgins is a
beneficial owner
For that relevant interest-
Number held in class before acquisition or disposal:
19,011
Number held in class after acquisition or disposal:
22,670
Current registered holder(s):
N/A
Registered holder(s) once transfers are registered:
Adam L Higgins Superannuation Fund
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
Multiple
Details of transactions requiring disclosure-
Date of transaction:
31 May 2022 to 3 June 2022
Nature of transaction:
On market purchases in accordance with the
Ryman directors' fixed share trading plan (for
the period from 1 October 2021 to 31 March
2022)
Name of any other party or parties to the transaction (if known):
N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$35,298.37 (being an average of $9.6470 per
share)
Number of financial products to which the transaction related:
3,659

If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal
Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
7 June 2022
Name and title of authorised person:David Bennett, Group Chief Financial Officer
Notes
Use this form to disclose all the acquisitions and disposals by a director or senior
manager of a listed issuer, or of a related body corporate, or in specified derivatives. The
disclosure must be made within—
(a)20 working days after the first acquisition or disposal disclosed in this
notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the
Financial Markets Conduct Act 2013; or
(
b)
in an
y other case, 5 trading days after the first acquisition or dispos
al
disclosed in this notice.